

Read on to learn more about IIVS at WC13 and Eurotox, **upcoming workshops**, Spanish-language training, contributor spotlight, calls for methods for validation, and recent publications.

See IIVS at the 13th World Congress in Rio

IIVS scientists will be speaking in or co-chairing several sessions at the upcoming **13th World Congress on Alternatives and Animal Use in the Life Sciences** which will be held in Rio de Janeiro, Brazil from August 31 - September 4, 2025. Mark your agenda for the following sessions!

Sunday August 31

Satellite Event - New Approach Methodologies for Evaluation of Agrochemical Formulations

Sunday 1:30 PM - 3:00 PM, Room 207

In this section, three lectures (including one from Kristie Sullivan) will focus on different aspects of alternative methods for evaluating the skin sensitization and irritation potential of agrochemical formulations.

Monday September 1

9:30 AM - 11:00 AM, Room 201

Session 84: Transitioning to Animal-Free Chemical Safety Assessment

Chairs: Kristie Sullivan, IIVS and Gavin Maxwell, Unilever

11:30 AM - 1:00 PM, Room 202

Session 77: Development of non-animal methods for the identification of respiratory sensitizers: Reconciling the differences in clinical diagnosis and regulatory policies



3RS Integrating 3 Worlds Human, Animal and Environmental Health

August 31 - September 4, 2025
Rio de Janeiro, Brazil

Presentation by Kristie Sullivan: *Need of the hour: Balancing scientific objectives with practical knowledge*

Tuesday September 2

11:30 AM - 1:00 PM, Room 201

Session 48: Confidence in in vitro alternatives to animal testing - defining standards to ensure rigorous and reproducible data

Presentation by Amanda Ulrey: *GIVIMP and its Role in In Vitro Regulatory Testing*

11:30 AM to 1:00 PM, Room 207

Session 43: Hands on Training in NAMs to Enhance Translational Success

Presentation by Kristie Sullivan: *Oh wow! How hands-on and experiential elements lead to impactful learning in toxicology*

Wednesday September 3

9:30 AM - 11:00 AM, Plenary Room

Session 102: The Future is Now: The Power of NAMs for a global acceptance for Local Tolerance

Presentation by Kristie Sullivan: *Empowering the Next Generation of Toxicologists: Designing Effective Educational Programs for New Approach Methodologies*

11:30 AM - 1:00 PM, Room 201

Session 29: Building Confidence and Transparency into Validation Management and Peer Review Track: Human Health - Policies

Co-chairs: Amanda Ulrey, IIVS and Emily Reinke, Inotiv

Presentation by Amanda Ulrey: *Assessing data integrity: a deep dive into data review in method validation*

11:30 AM - 1:00 PM, Room 202

Session 109: From internal decision making to regulatory approval: Finding strategies to accelerate the use of NAMs

Co-chairs: Kristie Sullivan, IIVS and Nicolas Fabre, L'Oreal

2:30 PM - 4:00 PM Room 203

Session 81: Breaking Down Silos to Achieve One Health - Integrating Environment into Education and Training Initiatives in Latin America and Beyond

Presentation by Kristie Sullivan: *How tools and training can help advance toxicology across disciplines*

Thursday September 4

9:30 AM - 11:00 AM, Plenary Room

Session 69: Replacing invisible animal suffering – Animal-free materials in cell and tissue culture
Presentation by Joseph Hughes: *Next-Generation Full-Thickness Human Skin Models Produced using 3D Electrospun Scaffolds and Animal-Component-Free Culture Media*

9:30 AM - 11:00 AM, Room 203



IIVS is exhibiting - visit us at Booth 13 to talk with us or set up an appointment, or learn more about our laboratory, education and training, and validation services.

Email Client Services to connect.


ICYMI - IIVS offering EpiSensaA

The Epidermal Sensitization Assay (EpiSensaA)(OECD 442D) is a next-generation, GLP-compliant method developed by the KAO Corporation. The EpiSensaA offers a reliable, human-relevant method for assessing skin sensitization potential, enhancing our ability to provide New Approach

Methodologies (NAMs)-based solutions that address industry challenges. The EpiSensaA quantifies the changes in the expression of genes associated with the activation of keratinocytes and cytoprotective pathways, corresponding to the second key event (KE-2) in the skin sensitization Adverse Outcome Pathway. The fold induction of four marker genes: ATF3, GCLM, DNAJB4, and IL-8, is analyzed through RT-qPCR.

The EpiSensaA has been adopted by the OECD and included in Test Guideline 442D and Guideline 497. Utilizing a reconstructed human epidermis (RhE) model, this assay effectively assesses a broad spectrum of chemicals, including lipophilic materials, pre-haptens, pro-haptens, finished products, and other substances that have traditionally been difficult to test. The use of a 3D tissue construct offers a more physiologically relevant model that closely mimics human tissue, enhancing the accuracy and reliability of sensitization assessments. IIVS brings nearly 30 years of experience in GLP-compliant in vitro testing to this new option for our sponsors.

[Find out more](#)






REGISTER NOW:
**ToxTracker Hands-on
Workshop at IIVS**
Right before the ASCCT Meeting!

Join IIVS experts and guest speakers from HESI, Enko Chem, and Toxys for an interactive 1-day practical workshop focused on the ToxTracker Assay, which uses 6 engineered GFP-reporter cell lines to investigate genotoxic potential and toxicological mode of action.

Lectures will focus on the science behind the assay and how the data can be applied in testing programs. Attendees will have the opportunity to view and participate in the conduct of the assay in the laboratory in small groups. Virtual participation is also available.



[Find out more and register](#)



ASCCT Meeting Abstract Submission and Registration Open

Abstract Deadline: August 30th

The 14th Annual ASCCT meeting will be held at IIVS this October. It will feature plenary lectures and sessions from NIH and FDA leadership and scientists, CE courses, and posters and oral presentations showcasing in vitro and computational toxicology.

GIVIMP Certification Program Expands with New Participants and Milestones

The Institute for In Vitro Sciences (IIVS) is pleased to announce several exciting developments in its Good In Vitro Method Practice (GIVIMP) Certification Program this spring. **Invitrolize**, the Luxembourg-based company known for its ALIsens® system—used to identify and differentiate respiratory sensitizers and irritants under air-liquid interface exposure conditions—has successfully completed the GIVIMP Certification process. This achievement highlights Invitrolize's commitment to scientific rigor and the advancement of high-quality in vitro methodologies.



The GIVIMP Certification Program continues to grow, welcoming **British American Tobacco Pre-Clinical Sciences Labs**, **ImmuOne**, **Guandong Biocell**, and **Shaanxi Biocell** as new participants. These organizations join a global network of commercial and research institutions committed to enhancing the reliability and reproducibility of in vitro methods through adherence to the OECD's GIVIMP guidance. Developed by IIVS, the certification program offers a flexible, audit-based approach that supports laboratories in implementing best practices tailored to their unique technologies and operational scopes. As the program expands, it fosters international collaboration and harmonization of standards, helping to build confidence in alternative testing methods and accelerate their adoption worldwide.

IIVS is also exhibiting at Eurotox 2025

****Come visit us at booth A67****



Contributor Spotlight: M·A·C Cosmetics



Founded in Toronto in 1984 by makeup artist Frank Toskan and salon owner Frank Angelo, **M·A·C Cosmetics** has made social responsibility central to its identity—championing inclusivity,

sustainability, and artistry-driven products. Through VIVA GLAM, M·A·C has raised over \$535 million to support equality for all worldwide. The company's responsible ethics also includes a commitment to play an active role in ending animal testing by supporting IIVS's efforts for nearly a decade, and to avoid testing their own products or ingredients on animals. This reliable support makes it possible to change requirements and practices globally and phase out animal testing once and for all.

Education and Training Update - NURA En Español

Together with the Physicians Committee for Responsible Medicine (PCRM), IIVS organized a spring webinar series in Spanish on non-animal methods.

The series included presentations from leading experts from Latin America and by IIVS Senior Toxicologist Dr. Argel Islas-Robles, with introductions and Q&A sessions led by Dr. Islas-Robles and Dr. Jon McCord from PCRM.

The first webinar featured Dra. María Laura Gutiérrez from the University of Buenos Aires and Director of the Laboratory of Alternative Methods. She presented on in vitro models for ocular irritation and their application in the assessment of cosmetics, agrochemicals, and cleaning products.


The second webinar featured Dr. Andrés Pareja López, an investigator in biology at the University CES in Medellín, Colombia and Scientific Director of the In Vitro Toxicity Laboratory. He presented on the implementation of the 3Rs in Columbia and the transition underway from 2-dimensional to 3-dimensional models for toxicology and research.

The final webinar featured Dr. Argel Islas-Robles, who presented the latest in vitro methods and defined approaches for dermal sensitization, along with reflections on their application in Latin America.

To watch any of the recordings, visit PCRM's NURA page [here](#).

Connect with us on LinkedIn to keep updated on our virtual educational events, and [please contact us](#) to explore training collaborations!





"These innovative approaches will advance safety testing, accelerate drug development, and enhance disease modeling. Ultimately, this will support more cost-effective and human-relevant results, compared to traditional models."

Stacey Adam, PhD
vice President of Science
Partnerships, FNIH

Seeking Concepts for NAMs Pilot Projects

The Foundation for the National Institutes of Health (FNIH) is inviting scientists to submit project ideas to help make drug development faster, safer and more human-relevant – reducing the reliance on animals in research laboratories. It's an exciting opportunity to help shape the future of innovative NAMs. The FNIH is especially looking for well-developed NAMs that are ready for a closer look to see if they can move toward formal acceptance by regulators. Learn more: <https://fnih.org/our-programs/validation-qualification-network-design-phase/nams-pilot-projects/>.

IIVS is proud to participate as a member of the Compliment-AIRE Validation Qualification Network Design Phase Steering Committee. If you have a promising NAM and would like to brainstorm about it with us, please reach out to clientservices@iivs.org.

Recent Publications

- [Development of Preliminary Candidate Surface Guidelines for Air Force-Relevant Dermal Sensitizers Using New Approach Methodologies](#)

We Want to Hear From You

IIVS is always interested in the needs and requests from researchers interested in advancing the awareness, acceptance and use of alternative methods. If you have any input on methodologies

of interest, please don't hesitate to contact us at clientservices@iivs.org.

Connect With Us



Institute for In Vitro Sciences, Inc. | 30 W. Watkins Mill Road Suite 100 | Gaithersburg, MD 20878 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)